These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 28106247

  • 21. Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor.
    Bairey O, Shacham-Abulafia A, Shpilberg O, Gurion R.
    Hematol Oncol; 2016 Dec; 34(4):184-192. PubMed ID: 26052918
    [Abstract] [Full Text] [Related]

  • 22. Diffuse large cell lymphomas: identification of prognostic factors and validation of the International Non-Hodgkin's Lymphoma Prognostic Index. A Hellenic Cooperative Oncology Group Study.
    Nicolaides C, Fountzilas G, Zoumbos N, Skarlos D, Kosmidis P, Pectasides D, Karabelis A, Giannakakis T, Symeonidis A, Papadopoulos A, Antoniou F, Pavlidis N.
    Oncology; 1998 Dec; 55(5):405-15. PubMed ID: 9732217
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP.
    Park MJ, Park SH, Park PW, Seo YH, Kim KH, Seo JY, Jeong JH, Kim MJ, Ahn JY, Hong J.
    J Clin Pathol; 2015 Sep; 68(9):733-8. PubMed ID: 25998512
    [Abstract] [Full Text] [Related]

  • 26. [Clinical characteristics and prognosis of diffuse large B-cell lymphoma].
    Yang BY, Yong WB, Zhu J, Zheng W, Zhang YT, Wang XP, Meng SN.
    Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):174-6. PubMed ID: 15946571
    [Abstract] [Full Text] [Related]

  • 27. Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era.
    Chen H, Zhong Q, Zhou Y, Qin Y, Yang J, Liu P, He X, Zhou S, Zhang C, Gui L, Yang S, Zhou L, Shi Y.
    BMC Cancer; 2022 May 27; 22(1):583. PubMed ID: 35624433
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Prognostic value of tumor necrosis at CT in diffuse large B-cell lymphoma.
    Adams HJA, de Klerk JMH, Fijnheer R, Dubois SV, Nievelstein RAJ, Kwee TC.
    Eur J Radiol; 2015 Mar 27; 84(3):372-377. PubMed ID: 25559168
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma.
    Ochi Y, Kazuma Y, Hiramoto N, Ono Y, Yoshioka S, Yonetani N, Matsushita A, Imai Y, Hashimoto H, Ishikawa T.
    Ann Hematol; 2017 Jan 27; 96(1):1-8. PubMed ID: 27641425
    [Abstract] [Full Text] [Related]

  • 34. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.
    Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN.
    Blood; 2014 Feb 06; 123(6):837-42. PubMed ID: 24264230
    [Abstract] [Full Text] [Related]

  • 35. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
    Pfreundschuh M, Kuhnt E, Trümper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, López-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N, MabThera International Trial (MInT) Group.
    Lancet Oncol; 2011 Oct 06; 12(11):1013-22. PubMed ID: 21940214
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Analysis of clinical and immunophenotypic features along with treatment outcomes of diffuse large B cell lymphoma patients, based on the involvement of nodal or extranodal primary sites.
    Wang C, Li W, Liu C, He H, Bai O.
    Blood Cells Mol Dis; 2016 Mar 06; 57():42-9. PubMed ID: 26852654
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.